Published in J Clin Invest on December 01, 1982
A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol (1985) 3.62
The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol (1990) 2.36
The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci U S A (1985) 1.46
Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects. Breast Care (Basel) (2008) 0.82
Immunological comparison between human and rat plasminogen activators in blood and the vessel wall. J Clin Pathol (1984) 0.81
Human tissue-type plasminogen activator. Production in continuous serum-free cell culture and rapid purification. Biochem J (1985) 0.81
Transport of urokinase across the intestinal tract of normal human subjects with stimulation of synthesis and/or release of urokinase-type proteins. J Clin Invest (1985) 0.81
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med (1978) 3.92
Isolation and characterization of urokinase from human plasma. J Biol Chem (1982) 1.47
Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun (1969) 1.44
Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates. J Biol Chem (1979) 1.39
Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature (1976) 1.17
Purification and characterization of human vascular plasminogen activator. Biochim Biophys Acta (1980) 1.01
No crossreaction between circulating plasminogen activator and urokinase. Thromb Res (1979) 0.97
Effect of urokinase antiserum on plasminogen activators: demonstration of immunologic dissimilarity between plasma plasminogen activator and urokinase. J Clin Invest (1968) 0.95
Demonstration of urokinase-related fibrinolytic activity in human plasma. Br J Haematol (1982) 0.92
The participation of plasma thromboplastin antecedent (Factor XI) in contact-activated fibrinolysis. Proc Soc Exp Biol Med (1980) 0.87
Reflex control of respiration in the anesthetized dog during prolonged exposure to positive radial acceleration. Acta Physiol Scand (1959) 0.82
Inhibition of death receptor signals by cellular FLIP. Nature (1997) 9.58
Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol (2000) 8.49
Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med (1999) 7.41
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature (1997) 6.23
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 6.02
BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science (2001) 4.79
Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet (2005) 3.97
BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med (2000) 3.43
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med (1998) 3.17
MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem (1998) 3.09
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (1998) 2.84
TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol (2000) 2.80
BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med (2000) 2.69
Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet (1999) 2.35
The tetraspanin CD63/lamp3 cycles between endocytic and secretory compartments in human endothelial cells. Mol Biol Cell (2000) 2.12
The rising tide of endstage renal failure from diabetic nephropathy type II--an epidemiological analysis. Nephrol Dial Transplant (1995) 2.06
Directed evolution of a fungal peroxidase. Nat Biotechnol (1999) 2.04
Quality control of mitigation methods for unusually high indoor radon concentrations. Health Phys (2001) 1.94
CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol (1995) 1.93
Purification, characterization, molecular cloning, and expression of two laccase genes from the white rot basidiomycete Trametes villosa. Appl Environ Microbiol (1996) 1.93
Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med (1983) 1.85
A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med (2000) 1.83
TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity (1997) 1.74
Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int J Cancer (1984) 1.72
Crystal structure of the type-2 Cu depleted laccase from Coprinus cinereus at 2.2 A resolution. Nat Struct Biol (1998) 1.70
Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J Immunol (1999) 1.68
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood (1988) 1.68
Pathophysiology of endotoxin shock in the primate. Am J Obstet Gynecol (1970) 1.65
Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ (1991) 1.65
Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis (2001) 1.62
Plasma protein map: an update by microsequencing. Electrophoresis (1993) 1.60
Rapid right ventricular pacing is an alternative to adenosine in catheter interventional procedures for congenital heart disease. Heart (2004) 1.57
Tritium intake by exposure to plastic case watches. Health Phys (1996) 1.56
Chronic non-bacterial osteomyelitis in children. Ann Rheum Dis (2005) 1.49
FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol (1998) 1.49
T cell costimulation by the TNF ligand BAFF. J Immunol (2001) 1.47
Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre? Eur J Nucl Med (2001) 1.47
[Imerslund's disease. Clinical and biological aspects. Apropos of 6 cases]. Arch Pediatr (1997) 1.44
Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood (1984) 1.44
Considerations by the European DNA profiling (EDNAP) group on the working practices, nomenclature and interpretation of mitochondrial DNA profiles. Forensic Sci Int (2001) 1.43
Primary structure of CD52. J Biol Chem (1995) 1.42
Microheterogeneity of serum glycoproteins and their liver precursors in patients with carbohydrate-deficient glycoprotein syndrome type I: apparent deficiencies in clusterin and serum amyloid P. J Lab Clin Med (1997) 1.42
The identification and characterization of four laccases from the plant pathogenic fungus Rhizoctonia solani. Curr Genet (1996) 1.41
Tritium exposure from plastic case watches. Lancet (1994) 1.40
ApoE genotype does not affect plasma tPA and PAI-1 antigen levels. Am J Med Genet (1997) 1.40
Edar/Eda interactions regulate enamel knot formation in tooth morphogenesis. Development (2000) 1.39
Hepatic ablation with use of radio-frequency electrocautery in the animal model. J Vasc Interv Radiol (1992) 1.39
Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2. EMBO J (1989) 1.38
Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb (1993) 1.38
DNA commission of the international society for forensic genetics: guidelines for mitochondrial DNA typing. Forensic Sci Int (2000) 1.37
Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J (1980) 1.37
Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood (1993) 1.35
The glycoinositol phospholipids of Leishmania mexicana promastigotes. Evidence for the presence of three distinct pathways of glycolipid biosynthesis. J Biol Chem (1993) 1.35
Aspiration of enlarged parathyroid glands for parathyroid hormone assay. Radiology (1983) 1.34
Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem (1986) 1.33
Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells. Mol Cell Biol (1987) 1.32
Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells. J Cell Biol (1987) 1.32
Characterization of the gene encoding an extracellular laccase of Myceliophthora thermophila and analysis of the recombinant enzyme expressed in Aspergillus oryzae. Appl Environ Microbiol (1997) 1.31
Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci U S A (1990) 1.31
Equine herpesvirus-2 E10 gene product, but not its cellular homologue, activates NF-kappaB transcription factor and c-Jun N-terminal kinase. J Biol Chem (1999) 1.30
Stage-specific binding of Leishmania donovani to the sand fly vector midgut is regulated by conformational changes in the abundant surface lipophosphoglycan. J Exp Med (1995) 1.30
Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood (1987) 1.29
FIST/HIPK3: a Fas/FADD-interacting serine/threonine kinase that induces FADD phosphorylation and inhibits fas-mediated Jun NH(2)-terminal kinase activation. J Exp Med (2000) 1.24
Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost (1984) 1.23
[Osteoporosis a disease requiring treatment or a physiologic osteopenia state? WHO definition in opposition to Utah Paradigm?]. Dtsch Med Wochenschr (2002) 1.23
Low larval vector survival explains unstable malaria in the western Kenya highlands. Trop Med Int Health (2006) 1.22
Pancreatoblastoma in childhood: clinical course and therapeutic management of seven patients. Med Pediatr Oncol (2001) 1.21
Characterization of laccases and peroxidases from wood-rotting fungi (family Coprinaceae). Appl Environ Microbiol (1998) 1.20
Necrosis of skin induced by coumarin in a patient deficient in protein S. BMJ (1989) 1.20
[Incidence of intramural digestive system hematoma in anticoagulation. Epidemiologic study and clinical aspects of 59 cases observed in Switzerland (1970-1975)]. Schweiz Med Wochenschr (1983) 1.19
Persistent multiple organ microcirculatory disorders in severe acute pancreatitis: experimental findings and clinical implications. Dig Dis Sci (2002) 1.18
Diversity and evolution of a newly emerged North American Type 1 porcine arterivirus: analysis of isolates collected between 1999 and 2004. Arch Virol (2007) 1.18
Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis (1992) 1.18
The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem (2000) 1.18
Inhibitory effects of the essential oil of chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymes. Life Sci (2005) 1.17
Multicenter study for the evaluation of a dedicated biopsy device for MR-guided vacuum biopsy of the breast. Eur Radiol (2002) 1.16
Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem (2000) 1.15
Thy-1 binds to integrin beta(3) on astrocytes and triggers formation of focal contact sites. Curr Biol (2001) 1.15
Two new tailoring enzymes, a glycosyltransferase and an oxygenase, involved in biosynthesis of the angucycline antibiotic urdamycin A in Streptomyces fradiae Tü2717. Microbiology (2000) 1.14
Structure of Leishmania lipophosphoglycan: inter- and intra-specific polymorphism in Old World species. Biochem J (1995) 1.14
Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost (1989) 1.12
Expression of p150 in cervical neoplasia and its potential value in predicting survival. Cancer (1998) 1.11
Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol (1995) 1.11
Antibacterial effects of cefroxadine, cephalexin and cephradine in a new in vitro pharmacokinetic model. J Antibiot (Tokyo) (1982) 1.11
Green fluorescent protein as a novel tool to measure apoptosis and necrosis. Cytometry (2001) 1.10
Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer (1986) 1.10
Complications following total knee replacement. Clin Orthop Relat Res (1977) 1.09